Insight, China's Pharmaceutical Industry

GSK’s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio

GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China’s National Medical Products Administration (NMPA) has granted...

Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026

The Beijing Municipal Medical Insurance Bureau, in coordination with nine other government bureaus, has released...

Company Drug

Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention

Fineline Cube Apr 7, 2026

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China’s National...

Company Drug

Gan & Lee Pharmaceuticals Launches China’s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer

Fineline Cube Apr 7, 2026

Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China’s National...

Company Drug

Amgen’s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response

Fineline Cube Apr 7, 2026

Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating...

Policy / Regulatory

China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized

Fineline Cube Apr 7, 2026

The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications...

Company Deals

Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform

Fineline Cube Apr 7, 2026

Genesis MedTech, a Singapore-based medical device innovator, has acquired a controlling stake in Nanjing TUGE...

Company Deals

Sansure Biotech to Acquire WWHS Biotech, Gaining Exclusive Infrared Fluorescence Platform for Full-Scenario IVD Expansion

Fineline Cube Apr 7, 2026

Sansure Biotech Inc. (SHA: 688289), a leading Chinese in vitro diagnostics (IVD) company, has entered...

Company Deals

Conmind Medical Raises $29M in Series C to Advance Brain-Computer Interface and Cardio-Cerebral Integrated Care Platform

Fineline Cube Apr 7, 2026

Conmind Medical, a China-based brain science and medical technology platform, has secured RMB 200 million...

Company Deals Legal / IP

Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software

Fineline Cube Apr 4, 2026

Siemens Healthineers AG (ETR: SHL) has entered into a strategic collaboration with Ruijin Hospital, a...

Company Drug

Zhuhai Rundu’s Higenamine Receives NMPA Approval as China’s First Category 1 Cardiac Stress Test Agent

Fineline Cube Apr 4, 2026

China’s National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1...

Company Drug

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Fineline Cube Apr 4, 2026

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China’s...

Company Deals

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

Fineline Cube Apr 4, 2026

Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong...

Company Drug

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Fineline Cube Apr 4, 2026

Youcare Pharmaceutical Group (SHA: 688658) announced that its YKYY018 aerosolized inhalation formulation has received approval...

Others

Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline

Fineline Cube Apr 4, 2026

Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the...

Company Drug

Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen

Fineline Cube Apr 4, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) announced that the European Commission has granted marketing...

Company Drug

Merck Launches Pivotal Phase 2b/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment

Fineline Cube Apr 4, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b/3...

Others

Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline

Fineline Cube Apr 4, 2026

Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253...

Company Drug

Bio-Thera Solutions Gains NMPA Clearance for Phase I/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors

Fineline Cube Apr 4, 2026

Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Deals

Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model

Fineline Cube Apr 3, 2026

Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply,...

Insight, China's Pharmaceutical Industry

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Novo Nordisk’s Wegovy Shows 21.6% Weight Loss in Early Responders – OASIS 4 Subgroup Analysis Reveals Clinically Meaningful Benefits Across Patient Populations

Ab&b Bio-Tech Launches Phase I/II Trial of Recombinant RSV Vaccine – CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability

GSK’s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention

Gan & Lee Pharmaceuticals Launches China’s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer

Amgen’s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response

China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized

Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform

Sansure Biotech to Acquire WWHS Biotech, Gaining Exclusive Infrared Fluorescence Platform for Full-Scenario IVD Expansion

Conmind Medical Raises $29M in Series C to Advance Brain-Computer Interface and Cardio-Cerebral Integrated Care Platform

Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software

Zhuhai Rundu’s Higenamine Receives NMPA Approval as China’s First Category 1 Cardiac Stress Test Agent

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline

Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen

Merck Launches Pivotal Phase 2b/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment

Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline

Bio-Thera Solutions Gains NMPA Clearance for Phase I/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors

Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model

You Missed

Novo Nordisk’s Wegovy Shows 21.6% Weight Loss in Early Responders – OASIS 4 Subgroup Analysis Reveals Clinically Meaningful Benefits Across Patient Populations

Ab&b Bio-Tech Launches Phase I/II Trial of Recombinant RSV Vaccine – CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Kanghong Pharma’s Gene Therapy KHN921 Receives FDA Approval for Hypertrophic Cardiomyopathy Trial – AAV9 Vector Targets MYBPC3 Mutations with Potential One-Time Treatment